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cases in 2004, prostate cancer is the most common
noncutaneous cancer in men in the United States
[1]. Despite an impressive scope of research
eﬀorts, diﬃcult challenges persist in various as-
pects of prostate cancer care, including diagnosis,
prognostication, and treatment.
First and foremost is a pressing need to
appropriately tailor therapeutic interventions to
the spatial extent and biologic aggressiveness of
disease for individual patients. Individualized
therapy for localized disease could signiﬁcantly
reduce the treatment-related morbidity incurred
by this population of patients but requires the
development of better measures to delineate and
characterize disease. At present, these measures
are limited to nonspeciﬁc prostate-speciﬁc antigen
(PSA) serum levels [2], histopathologic estimates
of tumor burden, and Gleason grading, which is
subject to random biopsy sampling error [3–5] and
insensitive digital rectal examinations that are
poorly reproducible among observers [6].
The authors believe that in the near future,
imaging will bridge the gap between characteriza-
tion of disease and individualized therapy. An
ability to visualize the complete extent and bi-
ologic proﬁle of prostate cancer with regard to
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.1016/j.mric.2005.04.012prostatic anatomy may counter biopsy sampling
error, enable appropriate patient selection for
local therapy, guide local therapy to the disease
rather than to the entire prostate gland, and pro-
vide a noninvasive means of monitoring progres-
sion or response to therapy.
Here, the authors review the studies that are
currently investigating the potential role of MR
imaging in guiding needle-based prostate inter-
ventions. This review omits studies that use MR
images for guidance of external beam radiother-
apy [7] and, instead, focuses primarily on inter-
ventional procedures that are conducted in the
MR imaging scanner room. The article starts with
a brief overview of the role of diagnostic MR
imaging in prostate cancer.
MR imaging for prostate cancer
It is unfortunate that there is no single imaging
method that embodies all of the optimal charac-
teristics for the integration of diagnostic and
interventional procedures for prostate cancer.
CT permits accurate spatial visualization of inter-
ventional devices (Fig. 1A) but does not provide
real-time feedback or adequate soft tissue de-
lineation. Transrectal ultrasound (TRUS) is the
current ‘‘gold standard’’ for guiding prostate
interventions due to its ease of use and real-time
image feedback. Soft tissue delineation is better
with TRUS than with CT, but most tumors are
not visible under ultrasound, and biologic pro-
ﬁling is currently limited [8]. In addition, accurate
visualization of interventional needles remains
challenging (see Fig. 1B). The interventionalghts reserved.
mri.theclinics.com
492 ATALAR & ME´NARDFig. 1. Interventional images during high dose rate brachytherapy show the superiority of MR imaging in depicting the
prostate anatomy and the interventional catheters. (A) CT scan image. (B) Transrectal ultrasound image. (C) MR image.needles and the prostate anatomy are clearly
visible in MR images (see Fig. 1C). From this
perspective, MR imaging is well suited for guid-
ance of interventional procedures. The principal
limitations to its routine use include a lack of real-
time feedback and a complex and technically
challenging environment.
A number of anatomic structures can be
clearly delineated on MR imaging, including the
distal prostatic urethra (up to the point of in-
sertion in the central gland), the central zone, the
peripheral zone, the prostatic capsule, the levator
ani, and the rectal mucosa [9]. On contrast-
enhanced MR images, the neurovascular bundles
can also be identiﬁed (Fig. 2) [10]. Diagnostic MR
imaging, however, has the potential to provide
more than high image resolution of the prostateanatomy. Endorectal coil MR imaging of the
prostate gland has demonstrated value for staging
and prognostication in patients with localized
disease [11–16]. When T2-weighted anatomic
images, which are sensitive but not speciﬁc for
malignancy, are combined with biologic imaging
techniques such as MR spectroscopic imaging
[17–20] and dynamic contrast-enhanced (DCE)
MR imaging [8], MR imaging may be able to
accurately identify predominant subsites of tumor
burden.
DCE MR imaging is a promising tool for
visualizing the vascular physiology of solid tu-
mors. With the advent of modern multislice
imaging techniques and data analysis tools, imag-
ing the entire prostate gland with high spatial and
temporal resolution using DCE MR imaging is
493MR-GUIDED INTERVENTIONS FOR PROSTATE CANCERFig. 2. Neurovascular bundle imaging. The neurovascular bundle (arrows) along the prostate gland can be visualized
post contrast three-dimensional TrueFISP images. Each panel represents contiguous axial slices at the prostate apex.
(From Citrin D, Ning H, Guion P, et al. Inverse treatment planning based on MRI for high dose rate prostate
brachytherapy. Int J Radiat Oncol Biol Phys 2005;61(4):1272; with permission.)feasible. In a recent study [8], the sensitivity and
speciﬁty of DCE MR imaging for localizing
malignancy in the peripheral zone were estimated
to be 87% and 74%, respectively, based on a sub-
jective coregistration to TRUS-guided biopsies.
This level of accuracy is not maintained in the
central gland (sensitivity 96%, speciﬁcity 46%)
because coexisting benign prostatic hyperplasia is
also characterized by high vascularity.
Kurhanewicz and colleagues [17] proposed
a three-dimensional MR spectroscopic imaging
technique for the detection of prostate cancer.
This promising method compares the ratios of
choline and creatine to citrate peak levels as
a marker of malignancy in the peripheral zone.
One of the main limitations of this MR spectro-
scopic imaging technique is the relatively long
data acquisition time and the low signal-to-noise
ratio inherent to spectroscopy. The use of large
voxels in the imaging protocol partially solves this
problem but introducs partial volume eﬀects
whereby small lesions may become invisible.
In addition to the techniques of T2-weighted
MR imaging, DCE MR imaging, and MR spec-
troscopic imaging, there are a number of com-
plementary techniques under investigation to
improve the diagnostic accuracy of MR imaging.
For example, tissue hypoxia, a known biomarker
associated with prostate cancer, can be interro-
gated using blood oxygen level–dependent imag-
ing techniques [21,22]. Diﬀusion maps of the
prostate gland can also be generated with MR
imaging, thus providing noninvasive information
related to interstitial ﬂuid pressure changes in
normal and malignant prostate tissue [23,24].Needle core biopsy
Currently, prostate biopsy is conducted under
TRUS guidance. Although a positive biopsy
result is a clear indication of cancer, a negative
biopsy result is often indeﬁnite and problematic
because it is known that the sextant biopsy pro-
cedure has a relatively low sensitivity and high
sampling error [25]. To address this problem, an
8- to 10-biopsy regimen, depending on prostate
size, has been proposed [26], with sensitivity
increasing up to 80%. Repeat sextant biopsy is
another approach, which further increases the
sensitivity of this approach [27]. Image-guided
biopsy may be the best approach to this problem,
but ultrasound can be blind to 40% of lesions,
which are isoechoic [28].
MR-guided biopsy may have an immediate
impact by improving the sensitivity of needle core
biopsies to detect prostate cancer, speciﬁcally for
those 20% of patients who have false-negative
biopsy results from sampling error when per-
formed under TRUS guidance [29]. By combining
tissue biopsy with MR imaging (ie, to directly
biopsy tissue regions with a suspicious MR
imaging appearance), the high sensitivity of MR
imaging [30] may be obtained while gaining the
speciﬁcity of tissue biopsy.
In addition, MR imaging guidance of needle
biopsies is a critical step in the histopathologic
validation of emerging MR imaging techniques
for prostate cancer delineation and characteri-
zation. These new imaging techniques must be
validated against gold standard measures to estab-
lish their accuracy, and in this case, the gold
494 ATALAR & ME´NARDstandard is prostate biopsy and histopathology.
Notable intraprostatic [31] and intratumoral [32]
biologic heterogeneity mandates millimeter coloc-
alization accuracy between tissue samples and
their corresponding image pixels. When prostate
MR imaging and tissue acquisition procedures are
performed in diﬀerent settings and at diﬀerent
times, however, spatial coregistration is fraught
with error.
Stereotactic needle placement under MR
imaging guidance enables two critical steps in
the coregistration of tissue and MR imaging data.
First, it directly guides biopsies to sites of sus-
pected tumor on MR imaging, and second, it
permits volumetric veriﬁcation and document-
ation of the actual biopsy location with regard
to MR imaging data.Investigators at Harvard University were the
ﬁrst to report MR-guided prostate biopsies, which
were performed in patients with suspicion of
prostate cancer who were not candidates for
the standard TRUS-guided technique because of
a previous proctocolectomy [33,34]. Using an
open-conﬁguration 0.5-T MR imaging scanner
and a pelvic coil, transperineal needle core bi-
opsies were performed with patients in the dorsal
lithotomy position. Sites deemed suspicious for
cancer on previously acquired diagnostic MR
imaging were subjectively correlated to corre-
sponding sites on the interventional MR imaging
images and speciﬁcally targeted through a stereo-
tactically registered perineal template (Fig. 3). A
nonconventional transgluteal approach has also
been reported using an open low-ﬁeld MRFig. 3. Images obtained during MR-guided diagnosis and treatment of prostate cancer in a 62-year-old man. (A)
Coronal view of the prostate gland and bladder. The tip of the biopsy needle has been placed through the perineum and
into the lesion, located in the right midportion of the gland. The template was used for accurate placement of the needle.
(B) Axial view of the prostate gland with the tip of the biopsy needle in the right midportion of the gland. (C) Real-time
intraoperative catheter placement in the sagittal plane during MR-guided prostate brachytherapy. The black spots are
previously deposited radioactive sources posterior to the needle. (From D’Amico AV, Cormack RA, Tempany CM.
MRI-guided diagnosis and treatment of prostate cancer. N Engl J Med 2001;344(10):776; with permission.)
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suspicious prostate lesions on diagnostic MR
imaging [35]. Diagnostic images were similarly
subjectively correlated to interventional MR im-
ages to deﬁne biopsy target sites. Using T1-
weighted sequences, 25 biopsy procedures were
performed successfully with MR guidance in all
cases without any side eﬀects or complications.
Alternatively, diagnostic MR images have been
rigidly coregistered to interventional ultrasound
images for guidance [36].
To circumvent the need for and the error
associated with deformable or rigid registration
of previously acquired diagnostic MR images,
transperineal biopsies have been performed under
direct MR imaging guidance in a cylindric 1.5-T
scanner [37]. To address the challenge of accessing
the perineum under the geometric constraint of
a 60-cm diameter bore, patients were positioned in
the left lateral decubitus position (Fig. 4). Biopsies
were again performed through a stereotactically
registered perineal template that in this case was
aﬃxed perpendicularly to a rigid endorectal coil,thereby increasing signal-to-noise ratio and image
quality. The mean biopsy-needle targeting accu-
racy of the stereotactic system was 2.1 mm.
Finally, two competing devices for transrectal
prostate biopsy in a cylindric 1.5-T scanner have
recently been developed [38,39] and clinically
tested in patients with prostate cancer [39,40].
The main advantage of the transrectal approach is
a shorter needle path length, which translates to
less tissue trauma and patient discomfort. For
access, patients are positioned prone on the MR
imaging table.
The ﬁrst MR-guided transrectal biopsy system
was developed at Charite´, Humboldt-Universita¨t
zu Berlin in cooperation with MRI Devices/Daum
(Schwerin, Germany). This device is made of
polyoxymethylene and consists of a base plate,
an adjustable arm, and a needle guide ﬁlled with
contrast material gel that can be visualized on MR
imaging. After the patient is positioned, the needle
guide is inserted into the rectum and connected to
the arm of the biopsy device (Fig. 5). The arm
enables the needle guide to be rotated, translatedFig. 4. Setup for transperineal biopsy in a conventional 1.5-T MR imaging scanner. (A) Prostate images are displayed
within the scanner room using stereotactic targeting software. (B) The patient is positioned in the left lateral decubitus
position. An endorectal coil is aﬃxed perpendicular to the perineal template. (From Menard C, Susil RC, Choyke P,
et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 2004;59(5):1417;
with permission.)
496 ATALAR & ME´NARDFig. 5. The endorectal biopsy system developed at Charite´, Humboldt-Universita¨t zu Berlin in cooperation with MRI
Devices/Daum. Passive markers are imaged to register the device with respect to the prostate. (From Beyersdorﬀ D,
Winkel A, Hamm B, et al. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology
2005;234(2):577; with permission.)forward and backward, and adjusted in height. In
addition, the insertion angle can be changed by
rotating the needle guide about a point inside the
rectum.
In the initial study, biopsies were obtained
from suspicious areas of the prostate (Fig. 6) in 12
patients by means of an MR imaging–compatible
automatic (n ¼ 5) or semiautomatic (n ¼ 7)
16-gauge core needle biopsy device (Double-Shoot
Biopsy Gun or Semi-Automatic Biopsy Gun;
MRI Devices/Daum). The authors reported thatof the 16 biopsy specimens from areas that were
highly suspicious for prostate cancer at prebiopsy
MR imaging, 8 were positive and 8 were negative.
Of the 24 biopsy specimens from moderately
suspicious areas, 4 showed prostate cancer and
20 showed no prostate cancer. Of the 57 speci-
mens from nonsuspicious areas, 2 showed pros-
tate cancer and 55 did not.
It is important to note that the investigators
did not use DCE MR imaging or MR spectro-
scopic imaging to identify the suspected tumorFig. 6. (A) Axial T2-weighted diagnostic MR image of the prostate showing suspicious lesions (arrows). (B) Sagittal
interventional image of the endorectal biopsy procedure. The arrow shows the location of the biopsy device. (From
Beyersdorﬀ D, Winkel A, Hamm B, et al. MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial
results. Radiology 2005;234(2):579; with permission.)
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strong correlation between MR imaging ﬁndings
and biopsy results. These results are very encour-
aging for the future widespread use of MR-guided
biopsy procedures.
The other transrectal biopsy device, the ‘‘access
to prostate tissue under MR imaging guidance’’
(APTMR imaging) system (Fig. 7) [38,40], consists
of a 23-mm diameter hollow endorectal sheath,
placed at the beginning of the procedure, that
remains immobile throughout the intervention.
The sheath includes an integrated 20-mm diameter
single-turn imaging coil surrounding an anterior
window that allows for needle access to the pro-
state.An18-mmdiameter cylindric needle guide ﬁts
inside the stationary rectal sheath and contains
three MR tracking microcoils (allowing for device
registration). Needle channels at 20 and 30 of
angulation permit transrectal needle access to the
prostate gland. The cylindric needle guide is
mounted on a positioning stage containing the
mechanism that converts the rotation of two
ﬂexible control rodsdeach extending to the edge
of the scanner boredinto the rotation and trans-
lation of the needle guide. Finally, the positioning
stage is attached to an immobilization arm
mounted on a linear rail.
Four MR-guided prostate biopsy procedures
have been reported to date with the APT MR
imaging system for the histomolecular validation
of DCE MR imaging [41]. Biopsy locations were
selected throughout the peripheral zone of the
prostate using T2-weighted fast spin-echo images
and DCE MR images. Subsequently, after insert-
ing the biopsy needle but before collecting the
tissue core biopsy, T1-weighted fast spin-echoimages were acquired to conﬁrm biopsy needle
placement accuracy. Fifteen tissue biopsies were
collected; the mean biopsy needle placement
accuracy was 1.8 mm (maximum error, 4.0 mm)
[41]. All biopsy cores were suitable for histologic
evaluation and for genomic and proteomic micro-
array proﬁling. These data demonstrate the feasi-
bility and value of stereotactic biopsies under MR
imaging guidance and veriﬁcation to provide
a platform for rigorous histopathologic and bi-
ologic validation of MR imaging techniques
(Fig. 8).
The APT MR imaging system has also been
adapted to a 3-T MR imaging scanner and tested
in six patients to date [41]. Because higher ﬁeld
strength translates to higher MR signal, the
authors expect an improvement in the resolution
of diagnostic images.
In summary, ﬁve diﬀerent techniques of MR-
guided prostate biopsy have been reported in the
clinical literature. Given the need and rationale
for needle guidance to be based on diagnostic-
quality MR images, the authors favor a stereotac-
tic approach without real-time image guidance
within a diagnostic scanner. One of the limitations
to a broader application of the latter cylindric
scanner techniques relates to the instability and
discomfort associated with the left lateral decubi-
tus and prone positions. Although spatially accu-
rate and robust, stereotactic guidance systems
mandate an immobile prostate gland. A number
of studies have shown that prostate motion is
greatly reduced when patients are positioned
supine, stemming from greater patient comfort
and reduced respiratory motion [42–44]. Supine
immobilization and perineal access in the cylindricFig. 7. The APT MR imaging system developed at the Johns Hopkins University. A stationary sheet minimizes the
motion of the prostate during rotation and translation of the needle guide. The position of the needle guide is determined
by active tracking coils.
498 ATALAR & ME´NARDFig. 8. Case example demonstrating the feasibility and integration of prostate interventional MR imaging for the
correlation of molecular biology and DCE MR imaging. The stationary interventional endorectal coil (*) is used for
diagnostic and interventional MR imaging. (A) DCE MR imaging at 120 seconds shows a small area of increased signal
intensity in the left peripheral zone of the prostate. Regions of interest (ROIs; red and blue) corresponding to the
subsequent needle biopsy voids (B, C) are deﬁned for image analysis. (E) Time-intensity curves (corrected for T1
heterogeneity) from each ROI are ﬁt to a general kinetic model convolution integral using an arterial input function
measured from the external iliac artery. The transfer constant Ktrans (corresponding to the magnitude of the
enhancement curve, unit minute1) and the rate constant kep (describing the rate of clearance, unit minute1) are thought
to reﬂect diﬀerences in the perfusion and microvascular permeability underlying each ROI, respectively. Hematoxylin-
eosin staining shows adenocarcinoma (D) corresponding in this case to higher Ktrans and kep than benign tissue (F).
cDNA microarray (G, J) and reverse-phase protein array (H, I; array probed with STAT3 antibody) analysis can be
performed on the biopsy cores. (From Menard C, Susil RC, Choyke P, et al. An interventional magnetic resonance
imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. Mol Imaging
2005;4(1):63–6; with permission.)scanner is only be possible with custom-designed
interventional MR imaging tables, which is the
subject of ongoing work. Finally, larger studies
are required to conﬁrm the clinical value and role
of MR-guided biopsy in patients with prostate
cancer.Brachytherapy
Permanent implant
For patients with localized prostate cancer at
low risk for extraprostatic extension, permanent-
seed brachytherapy is an accepted and eﬀective
499MR-GUIDED INTERVENTIONS FOR PROSTATE CANCERminimally invasive treatment strategy. Radioac-
tive seeds are conventionally placed and left
throughout the prostate gland under ultrasound
guidance using a transperineal template. One
important performance measure of the procedure
is the proportion of the prostate gland receiving
the minimum desired dose. Treatment-related
toxicity is associated with radiation dose delivered
to the surrounding normal organs, including the
urethra, bladder wall, rectal wall, penile bulb, and
neurovascular bundles.
In an eﬀort to avoid toxicity with permanent-
seed brachytherapy, investigators at Harvard
University translated the conventional transper-
ineal ultrasound technique to an open MR
imaging scanner architecture [45]. Even at low
ﬁeld strength, the peripheral zone of the prostate
gland (where most cancers are known to reside)
could be distinguished from the central gland,
thus permitting partial prostatic irradiation
whereby permanent seeds were placed in the
peripheral zone only, thereby reducing the radia-
tion dose to the urethra and bladder wall (Fig. 9).
Five-year results conﬁrmed the equivalence of this
approach to radical prostatectomy in biochemical
disease-free survival [46].
Ultrasound or low-ﬁeld interventional MR
images, however, cannot accurately identify pros-
tatic subsites of tumor burden that may beneﬁt
from targeted radiation dose escalation. For this
reason, a number of investigators have attempted
to coregister previously acquired diagnostic MR
images to interventional images using techniques
ranging from subjective interpretation to ﬁnite
element–based deformable registration [47–52].
Permanent-seed brachytherapy performed directly
in a high-ﬁeld diagnostic scanner would circum-
vent this step and potentially reduce the error
introduced by coregistration. This methodology is
currently being investigated in the Netherlands,
where the technical feasibility of a novel single-
needle technique has been proposed [53].
Temporary implant
Patients with intermediate- or high-risk pros-
tate cancer have a higher intraprostatic burden
of disease. A number of prospective randomized
studies have conﬁrmed that such patients may
beneﬁt from escalation of radiation dose [54–56].
By virtue of the ‘‘inverse square’’ law, brachy-
therapy ‘‘radiation boosts’’ result in a much
steeper dose gradient and, hence, can achieve
better sparing of adjacent normal structurescompared with external beam radiotherapy.
Such a highly desirable quality can paradoxically
lead to important errors; therefore, the technique
demands a high level of accuracy and precision
and mandates optimal image guidance.
High dose rate temporary implants oﬀer sev-
eral advantages over permanent-seed implants.
Dosimetric calculations are performed immedi-
ately following the catheter placement procedure,
which permits the treatment plan to be based on
the actual geometry of the implant relative to the
anatomy. The treatment is immediately delivered
with an afterloading technique, and problems
with organ motion, setup error, and postimplant
edema are circumvented. A single high-intensity
192Ir source can be placed at any position for any
length of time within each needle. These two
variables (dwell position and dwell time) can be
optimized using computer programs designed to
achieve dose distribution that conforms to the
target volume, while limiting dose to normal
structures at risk of radiation injury.
Investigators at the University of California–
San Francisco have manually aligned previous
diagnostic MR imaging/MR spectroscopic imag-
ing datasets to ‘‘treatment planning’’ CT or MR
images acquired after brachytherapy catheters
were inserted into the prostate gland under ul-
trasound guidance [57]. Based on the diagnostic
images, subprostatic sites suspicious for tumor
burden that were speciﬁcally targeted for further
dose escalation were deﬁned. It was found that
the dose could be safely escalated to these sites
without overdosing the urethra or the rectum.
To circumvent the error associated with cor-
egistration of previously acquired diagnostic im-
ages, a technique for transperineal placement of
brachytherapy catheters in a 1.5-T scanner was
developed [37]. This technique is identical to the
biopsy technique described previously, whereby
patients are placed under general anesthesia in the
left lateral decubitus position on the MR imaging
table. This approach permits diagnostic images
to be acquired ﬁrst, followed immediately by the
placement of brachytherapy catheters throughout
the prostate gland. After the catheters are in place,
a ﬁnal diagnostic-quality T2-weighted image set
can be acquired and directly used to plan and
optimize radiation delivery [58]. The authors have
used this approach to demonstrate a unique
ability to limit radiation dose to the neurovascular
bundleda structure critical to sexual functiond
which is immediately adjacent to the prostate
gland and best visualized on MR imaging [10].
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501MR-GUIDED INTERVENTIONS FOR PROSTATE CANCERFig. 10. High dose rate brachytherapy in a 1.5-T scanner. (A) Fourteen brachytherapy catheters (signal voids) were
placed throughout the prostate gland and at sites of visualized extracapsular extension (arrow). (B) Radiation was
delivered according to a dosimetry plan whereby the target volume including the prostate gland and extracapsular sites
of disease extension (purple line) is encompassed by 100% of the prescription dose (outer yellow outline). The urethral
dose (orange outline) is kept below 125% of the prescription dose, and the rectal mucosa (white outline) is kept below
75% of the prescription dose. (FromMenard C, Susil RC, Choyke P, et al. MRI-guided HDR prostate brachytherapy in
standard 1.5T scanner. Int Radiat Oncol Biol Phys 2004;59(5):1420; with permission.)This procedure may also oﬀer a therapeutic ad-
vantage for those patients who have extracapsular
extension of disease visualized on MR images,
whereby extracapsular disease may be included in
the radiation target volume (Fig. 10).
Thermal therapy
The role of thermal therapies for patients with
prostate cancer remains investigational at this
time. Beyond anatomic guidance, there is a strong
rationale for integrating thermal treatment, spe-
ciﬁcally heat therapy, in the MR imaging envi-
ronment where temperature can be monitored
noninvasively during the procedure [59]. This
treatment has been demonstrated by Chen and
colleagues [60], whereby patients who had locally
recurrent prostate carcinoma received percutane-
ous interstitial microwave thermoablation con-
tinually guided with MR imaging. Four MR
imaging–compatible microwave applicators were
placed in the four quadrants of the prostate gland
under ultrasound guidance. Patients were trans-
ferred to MR imaging, where treatment wasdelivered while phase images were obtained with a
rapid gradient-echo technique to derive tissue
temperature change on the basis of proton-reso-
nance frequency shift (Fig. 11).
Prostate treatments with high-intensity focused
ultrasound under MR imaging guidance with
a transurethral [61,62] or transrectal [63] approach
have been reported in the literature only at the
preclinical stage to date.
Summary
MR imaging is currently the most eﬀective
diagnostic imaging tool for visualizing the anatomy
and pathology of the prostate gland. Currently,
the practicality and cost eﬀectiveness of transrectal
ultrasound dominates image guidance for needle-
based prostate interventions. Challenges to the
integration of diagnostic and interventional MR
imaging have included the lack of real-time feed-
back, the complexity of the imaging technique,
and limited access to the perineum within the
geometric constraints of the MR imaging scanner.Fig. 9. MR-guided permanent seed brachytherapy in an open MR imaging scanner. (A) Series of axial T2-weighted MR
images used to identify the clinical target volume, the anterior rectal wall, and the prostatic urethra. (B) Series showing
segmentation of the prostate peripheral zone, the anterior rectal wall, and the prostatic urethra. (C) Series after total
dose received based on ﬁnal 125iodine source positions. Red, R240 Gy; yellow, R160 and !240 Gy; blue, R100 and
!160 Gy; no color, !100 Gy. (From D’Amico AV, Cormack R, Tempany CM, et al. Real-time magnetic resonance
image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J
Radiat Oncol Biol Phys 1998;42(3):513; with permission.)
;
502 ATALAR & ME´NARDTwo basic strategies have been explored and
clinically demonstrated in the literature: (1) cor-
egistration of previously acquired diagnostic MR
imaging to interventional TRUS or open scanner
MR images, and (2) stereotactic needle interven-
tionswithin conventional diagnostic scanners using
careful patient positioning or the aid of simple
manipulators.
Currently, researchers are developing techni-
ques that render MR imaging the method of
choice for the direct guidance of many proce-
dures. This article focuses on needle-based inter-
ventions for prostate cancer, including biopsy,
brachytherapy, and thermal therapy. With rapid
progress in biologic imaging of the prostate gland,
the authors believe that MR imaging guidance
will play an increasing role in the diagnosis and
treatment of prostate cancer.
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